The EQ-HWB: Overview of the Development of a Measure of Health and Wellbeing and Key Results.

EQ-HWB carer outcomes health and wellbeing outcome measures preference-based measures quality-adjusted life-years social care outcomes utilities

Journal

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
ISSN: 1524-4733
Titre abrégé: Value Health
Pays: United States
ID NLM: 100883818

Informations de publication

Date de publication:
04 2022
Historique:
received: 08 06 2021
revised: 04 01 2022
accepted: 23 01 2022
pubmed: 13 3 2022
medline: 6 4 2022
entrez: 12 3 2022
Statut: ppublish

Résumé

Existing measures for estimating quality-adjusted life-years are mostly limited to health-related quality of life. This article presents an overview of the development the EQ-HWB (EQ Health and Wellbeing), which is a measure that encompasses health and wellbeing. Stages: (1) Establishing domains through reviews of the qualitative literature informed by a conceptual framework. (2) Generation and selection of items to cover the domains. (3) Face validation of these items through qualitative interviews with 168 patients, social care users, general population, and carers across 6 countries (Argentina, Australia, China, Germany, United Kingdom, United States). (4) Extensive psychometric testing of candidate items (using classical, factor analysis, and item response theory methods) on > 4000 respondents in the 6 countries. Stakeholders were consulted throughout. A total of 32 subdomains grouped into 7 high-level domains were identified from the qualitative literature and 97 items generated to cover them. Face validation eliminated 36 items, modified 14, and added 3. Psychometric testing of 64 items found little difference in missing data or problems with response distribution, the conceptual model was confirmed except in China, and most items performed well in the item response theory in all countries. Evidence was presented to stakeholders in 2 rounds of consultation to inform the final selection of items for the EQ-HWB (25-item) and the short version of EQ-HWB (9-items). EQ-HWB measures have been developed internationally for evaluating interventions in health, public health, and social care including the impact on patients, social care users, and carers.

Identifiants

pubmed: 35277337
pii: S1098-3015(22)00083-3
doi: 10.1016/j.jval.2022.01.009
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

482-491

Subventions

Organisme : Medical Research Council
ID : 170620
Pays : United Kingdom

Informations de copyright

Copyright © 2022. Published by Elsevier Inc.

Auteurs

John Brazier (J)

School of Health and Related Research, The University of Sheffield, Sheffield, England, UK; Melbourne School of Population and Global Health, University of Melbourne, Australia. Electronic address: j.e.brazier@sheffield.ac.uk.

Tessa Peasgood (T)

School of Health and Related Research, The University of Sheffield, Sheffield, England, UK.

Clara Mukuria (C)

School of Health and Related Research, The University of Sheffield, Sheffield, England, UK.

Ole Marten (O)

Department of Health Economics and Health Care Management, School of Public Health, Bielefeld University, Bielefeld, Germany.

Simone Kreimeier (S)

Department of Health Economics and Health Care Management, School of Public Health, Bielefeld University, Bielefeld, Germany.

Nan Luo (N)

Saw Swee Hock School of Public Health, National University of Singapore, Singapore.

Brendan Mulhern (B)

Centre for Health Economics Research and Evaluation, University of Technology Sydney, Australia.

A Simon Pickard (AS)

Department of Pharmacy Systems, Outcomes and Policy, College of Pharmacy, University of Illinois at Chicago, IL, USA.

Federico Augustovski (F)

Institute for Clinical Effectiveness and Health Policy (IECS-CONICET), Buenos Aires, Argentina.

Wolfgang Greiner (W)

Department of Health Economics and Health Care Management, School of Public Health, Bielefeld University, Bielefeld, Germany.

Lidia Engel (L)

Deakin Health Economics, School of Health and Social Development, Deakin University, Australia.

Maria Belizan (M)

Institute for Clinical Effectiveness and Health Policy (IECS-CONICET), Buenos Aires, Argentina.

Zhihao Yang (Z)

Health Services Management Department, Guizhou Medical University, Guizhou, China.

Andrea Monteiro (A)

Department of Pharmacy Systems, Outcomes and Policy, College of Pharmacy, University of Illinois at Chicago, IL, USA.

Maja Kuharic (M)

Department of Pharmacy Systems, Outcomes and Policy, College of Pharmacy, University of Illinois at Chicago, IL, USA.

Luz Gibbons (L)

Institute for Clinical Effectiveness and Health Policy (IECS-CONICET), Buenos Aires, Argentina.

Kristina Ludwig (K)

Department of Health Economics and Health Care Management, School of Public Health, Bielefeld University, Bielefeld, Germany.

Jill Carlton (J)

School of Health and Related Research, The University of Sheffield, Sheffield, England, UK.

Janice Connell (J)

School of Health and Related Research, The University of Sheffield, Sheffield, England, UK.

Stacey Rand (S)

Personal Social Services Research Unit, University of Kent, Canterbury, England, UK.

Nancy Devlin (N)

School of Health and Related Research, The University of Sheffield, Sheffield, England, UK; Melbourne School of Population and Global Health, University of Melbourne, Australia.

Karen Jones (K)

Personal Social Services Research Unit, University of Kent, Canterbury, England, UK.

Aki Tsuchiya (A)

School of Health and Related Research, The University of Sheffield, Sheffield, England, UK.

Rosemary Lovett (R)

School of Health and Related Research, The University of Sheffield, Sheffield, England, UK; National Institute for Health and Care Excellence, London, England, UK.

Bhash Naidoo (B)

National Institute for Health and Care Excellence, London, England, UK.

Donna Rowen (D)

School of Health and Related Research, The University of Sheffield, Sheffield, England, UK.

Juan Carlos Rejon-Parrilla (JC)

National Institute for Health and Care Excellence, London, England, UK; Andalusian Agency for Health Technology Assessment, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH